We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Salmeterol Xinafoate as Maintenance Therapy Compared With Albuterol in Patients With Asthma

Gilbert E. D'Alonzo, DO; Robert A. Nathan, MD; Stuart Henochowicz, MD; Richard J. Morris, MD; Paul Ratner, MD; Stephen I. Rennard, MD
JAMA. 1994;271(18):1412-1416. doi:10.1001/jama.1994.03510420044032.
Text Size: A A A
Published online


Objective.  —To compare the efficacy and safety of inhaled salmeterol xinafoate, a long-acting β2-adrenoceptor agonist, with that of albuterol, a short-acting inhaled β2-agonist, in the treatment of asthma.

Design.  —Randomized, double-blind, placebo-controlled, parallel-group study.

Setting.  —Eleven outpatient clinical centers.

Subjects.  —A total of 322 male and female patients at least 12 years of age with chronic symptomatic asthma requiring daily therapy.

Intervention.  —Patients were treated with salmeterol xinafoate (42 μg inhaled twice daily), albuterol (180 μg inhaled four times daily), or placebo (four times a day) for 12 weeks; patients in all three groups could use inhaled albuterol as backup medication for breakthrough symptoms.

Main Outcome Measures.  —Serial 12-hour forced expiratory flow in 1 second (FEV1), peak expiratory flow (PEF), asthma symptoms, nocturnal awakenings due to asthma, episodes of asthma exacerbations, and electrocardiography.

Results.  —The mean area under the curve for FEV1 throughout each 12-hour period was consistently greater after a single dose of salmeterol than after two doses of albuterol administered 6 hours apart (P<.001), with the difference ranging from 3.1 to 4.3 L·h. Salmeterol produced an average increase in morning and evening PEF of 26 and 29 L/min, respectively, over pretreatment values compared with decreases of —13 and —3 L/min, respectively, in the albuterol group and —2 L/min both in the morning and evening in the placebo group (P<.001). Patients in the salmeterol group had significantly fewer days and nights with symptoms than did either the albuterol or placebo group (P<.001). Responses to salmeterol were similar at day 1 and at week 12. Adverse events in all treatment groups were equally infrequent, and no clinically significant change in cardiac rhythm was observed with salmeterol treatment.

Conclusion.  —Salmeterol inhaled twice daily is more effective than albuterol inhaled four times a day (or as needed) in patients with asthma requiring maintenance therapy. No deterioration of asthma control was observed with the use of salmeterol over a 3-month period.(JAMA. 1994;271:1412-1416)


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.